Clinical Trial Update: Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory T(11;14) Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update announcing a Phase 1/2 study of belantamab mafodotin plus venetoclax for relapsed/refractory t(11;14) multiple myeloma, currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Belantamab mafodotin (Blenrep) (belantamab mafodotin)
• Venetoclax (venetoclax)

Snippet

Sponsor: Universitätsklinikum Hamburg-Eppendorf | Conditions: Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1, Phase 2 | Status: RECRUITING